Good morning, everyone. Plenty of headlines to bring you this week, with deals and IPOs across medical devices and biotech. Headlines include longevity, diagnostics, more AI, and endoscopy. Let me know if I missed any.
➡️ Pfizer is paying Innovent $650m upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage China’s fast early development system.
➡️ Human Longevity, which is seeking to use biology and genomics to boost the human lifespan, has launched a new company called Human Life Foundation Models to help with its goal.
➡️ Apogee Therapeutics has secured a promise of up to $1.3bn in financing from Blackstone Life Sciences (BXLS) as the biotech gears up to take its anti-IL-13 antibody into phase 3.
➡️ Olympus has signed a definitive agreement to acquire BioProtect for $270m, adding biodegradable balloon spacer technology to its portfolio as the company broadens beyond its endoscopy stronghold.
➡️ Ex-Palantir execs raise $12M to develop AI operating system at Perceptic that has developed software to help other companies connect data, decisions and context across the drug lifecycle.
➡️ Basel-based Nuclidium AG has secured an additional tranche for its ongoing Series B financing round, bringing the total to approximately €115m.
➡️ French immunotherapy developer OSE Immunotherapeutics has signed a term sheet for a flexible bridge equity financing with IRIS Capital Investment, giving the Nantes- and Paris-based biotech access to up to €19.3m in gross proceeds over 24 months.
➡️ Countable Labs has raised $26m to advance the development and commercialisation activities for its single-molecule PCR technology.
➡️ Secretome Therapeutics Announces $30m Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy
➡️ Protuoso Biosciences Raises $9.5M Seed Financing for Hub-and-Spoke Platform to Advance Multifunctional MUXBODY™ Biologics
➡️ Phytolon, a biotechnology company developing natural, fermentation-based food color solutions, has completed a $23.6 million Series B funding round aimed at commercializing its natural food colors in the United States
➡️ Novo Holdings portfolio company Limmatech today announced a definitive agreement to be acquired by Eli Lilly and Company.
Congratulations to all involved 👏